Pentetreotide

Summary

Pentetreotide (CHEMBL2108757) is a phase-3 clinical-stage protein; indicated across 1 condition including neuroendocrine neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Protein
• Indications: 1 condition
• Clinical trials: 1

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108757
Name	Pentetreotide
Type	Protein
Max phase	3

Also known as: (-)-pentetoreotide, DTPA-SMS, Pentetoreotide, Pentetreotida, Pentetreotide, SDZ-215811, PENTETREOTIDE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
neuroendocrine neoplasm	2	MONDO:0019496	EFO:1001901

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00001849	PHASE2	COMPLETED	New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing Syndrome

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).